Compare Mesoblast Limited (MESO) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Vale SA — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Vale SA trades at $14.26 (market cap $59.07B). The key difference: Vale SA is far larger — about 27.2× Mesoblast Limited's market cap, and Vale SA pays a 8.93% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | VALE | |
|---|---|---|
Market Cap | $2.17B | $59.07B |
Sector | Technology | Basic Materials |
52-Week High | $20.96 | $17.82 |
52-Week Low | $12.88 | $9.53 |
Enterprise Value | $2.17B | $75.99B |
Dividend Yield | — | 8.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
VALE trades at $14.08, down 0.78% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported $38.4B revenue for 2025 with net income of $2.35B, though earnings have missed expectations in two of the last three quarters. Recent news highlights governance challenges and a $2.6B decarbonization investment plan announced in June 2026.
While analyst consensus remains cautiously optimistic with a $17.63 price target, declining profit margins and recent earnings misses present headwinds. The stock offers value with reasonable P/E and EV/EBITDA multiples, but investors face risks from commodity price volatility and execution challenges in the company's strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
